

## **DECLARATION**

I, Alick Mwambungu, do hereby declare that this dissertation presents my own work and that all the sources I have quoted have been indicated and acknowledged by means of complete references. I further declare that this dissertation has not previously been submitted for a degree, diploma or other qualifications at this or another University. It has been prepared in accordance with the guidelines of Master of Science Dissertations of the University of Zambia.

Signature..... Date:.....

**Alick Mwambungu**

### **Supervisor**

Signature..... Date:.....

**Dr Lydia Korolova**

### **Co-Supervisor**

Signature..... Date:.....

**Dr Trevor Kaile**

## **CERTIFICATE OF APPROVAL**

This dissertation of Alick Mwambungu is approved as partial fulfillment of the requirement for the award of the degree of Master of Science in Pathology (Haematology) by the University of Zambia.

Examiner: 1 ..... Date.....

Examiner: 2 ..... Date.....

Examiner: 3 ..... Date.....

### **Head of Department:**

Signature..... Date.....

Department of Pathology and Microbiology, University of Zambia.

## **ACKNOWLEDGEMENTS**

I wish to express my sincere gratitude to management at Ndola College of Biomedical Sciences, for having given me study leave to undertake a Master of Science Course in Haematology at The University of Zambia.

I am also grateful to all the nurses and laboratory staff at Ndola Central Hospital that accorded me chance to conduct my studies in a suitable environment.

I further wish to pay tribute to my Supervisor, Dr Lydia Korolova for the tireless guidance and support rendered throughout the proposal development, research work and write up of this dissertation. Furthermore, I wish to thank my co-supervisor Dr Trevor Kaile for his guidance, encouragement and critical analysis of the work. My other gratitude goes to Dr Yusuf Ahmed, for creating time off his busy schedule to guide me on the proposal and dissertation write-up.

Finally, I whole heartedly thank all those too numerous to mention who helped in one way or another to make this a reality. May the almighty God, bless them all.

## **DEDICATION**

I wish to dedicate this work to my family for the encouragement I got from the beginning of my studies. To my wife Chiti and my children Naomi, Chikutwe and Sean, your understanding and patience helped me achieve what looked like an impossible journey especially when priorities changed, with school taking up most of the financial share at the expense of what the majority might consider necessities in life.

## **COPYRIGHT**

All rights reserved. No part of this dissertation may be reproduced, stored in any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission from the author or the University of Zambia.

## ABSTRACT

**Background:** Patients with diabetes mellitus have a high risk of atherothrombotic events. Eighty percent of patients with diabetes mellitus die due to thrombosis, and 75% of these deaths are due to cardiovascular complications. A cross-sectional analytical study was conducted at Ndola Central Hospital between November 2012 and April 2013 with the main objective of determining the hypercoagulability state of type 2 diabetes mellitus (T2DM) patients.

**Method:** Prothrombin time (PT), Activated partial thromboplastin time (APTT), von Willebrand's factor (vWF) and Fibrinogen concentrations were measured in 213 T2DM patients and 172 non-diabetic healthy participants. vWF and fibrinogen were used as proxy biomarkers for hypercoagulability in T2DM patients. A structured questionnaire was used to capture Age, sex, duration of diabetes mellitus and knowledge on T2DM of study participants. Body weight and body height were also measured and Body mass index (BMI) calculated.

**Results:** The mean fibrinogen concentration for T2DM patients ( $4.3 \pm 2.5$ g/l) was significantly higher than control participants ( $2.3 \pm 1.6$ g/l). Mean vWF concentration was also significantly higher in T2DM patients ( $7.4 \pm 4.1$  IU/ml) than in control participants ( $2.6 \pm 2.2$  IU/ml)  $P=0.004$ . The mean APTT in T2DM patients was significantly shorter than in control study participants  $P=0.000$ . Prevalence of hypercoagulability among T2DM patients was significantly higher [126(59.2%)] than in the control participants [22(12.7%)]. Female type 2 diabetic participants had higher proportion of hypercoagulability than male participants 88(73.3%) and 38(40.9%) respectively  $P=0.000$ . Age, Sex, glycaemic control, Obesity and duration of T2DM were found to be independent risk factors for hypercoagulability in T2DM participants with the AOR of 4.42(95% CI 2.77-10.63), 1.45(95% CI 1.19-3.16), 6.12(95% CI 2.27-8.36), 5.28 (95% CI 3.01-8.21), 4.54(95% CI 2.88-10.59) and 5.28(95% CI 3.01-8.21) respectively. APTT was found to be a probable marker of hypercoagulability in T2DM patients due to its high sensitivity (93.7%), Specificity (95.4%) PPV (96.7%), NPV (91.2%) and had a strong statistically significant correlation with vWF;  $R= -0.783$   $P=0.001$ .

**Conclusion:** T2DM patients are more hypercoagulable than non-diabetic healthy individuals and female T2DM patients were more hypercoagulable than male patients. APTT may be introduced as a marker for hypercoagulability in T2DM after conducting a prospective study to follow-up T2DM patients and determine how many will develop thrombosis in future.

## TABLE OF CONTENTS

<b>Item</b>	<b>Page</b>
Declaration.....	i
Certificate of Approval.....	ii
Acknowledgements.....	iii
Dedication.....	iv
Copyright.....	v
Abstract.....	vi
<b>CHAPTER ONE: INTRODUCTION</b> .....	<b>1</b>
1.0 Background.....	1
1.1 Statement of the problem.....	3
1.2 Study justification.....	4
1.3 Hypothesis.....	6
1.4 General objectives.....	6
1.5 Specific Objectives.....	6
<b>CHAPTER TWO: LITERATURE REVIEW</b> .....	<b>7</b>
2.1 Risk factors for hypercoagulability in type 2 diabetes mellitus patients.....	8
2.1.1 Age.....	8
2.1.2 Social Economic Status .....	8
2.1.3 Glycaemic control.....	9
2.1.4 Duration of type 2 diabetes mellitus and hypercoagulability .....	10
2.1.5 Hypercholesterolemia, Obesity and hypertension .....	10
2.2. Mechanisms of hypercoagulability in type 2 Diabetes mellitus patients.....	13
2.2.1 Endothelial Dysfunction.....	13
2.2.2 Coagulative activation.....	15
2.2.3 Platelet activation.....	18
2.2.4 Disturbances of fibrinolysis.....	19

2.3 Haemostatic profile of type 2 diabetes Mellitus patients .....	21
2.3.1 Fibrinogen and Vonwillebrands factor.....	21
2.3.2 Prothrombin and Activated Partial Thromboplastin.....	26
<b>CHAPTER THREE: RESEARCH DESIGN AND METHODOLOGY .....</b>	<b>29</b>
3.1 Research site.....	29
3.2 Study population and design.....	29
3.3 Inclusion criteria.....	29
3.4 Exclusion criteria.....	29
3.5 Sample size.....	30
3.6 Sampling.....	31
3.7 Variables and Indicators of Measurements.....	31
3.8 Ethical consideration.....	34
3.9 Data collection.....	35
3.9.1 Questionnaire and laboratory request forms.....	35
3.9.2 Physical measurements.....	35
3.10 Laboratory Tests.....	36
3.10.1 Random blood glucose.....	36
3.10.2 Total Cholesterol estimation.....	37
3.10.3 Prothrombin Time and Activated Partial Thromboplastin Time.....	37
3.10.4 Plasma fibrinogen determination.....	38
3.10.5 Vonwillebrands factor estimation.....	38
3.10.6 Glycated haemoglobin estimation.....	39
3.11 Determination of haemostatic profile in type 2 diabetes mellitus.....	39
3.12 Prevalence of hypercoagulability in type 2 diabetes mellitus.....	39
3.13 Risk factors and patient attributes associated with hypercoagulation.....	39
3.13.1 Association of Age and hypercoagulability.....	40
3.13.2 Glycaemic control and hypercoagulation.....	40
3.13.3 Knowledge about type 2 diabetes mellitus risk factors and complications.....	40

3.13.4 Duration of type 2 diabetes mellitus and the risk of hypercoagulation.....	41
3.14 Suitability of PT and APTT as hypercoagulation markers.....	41
3.15 Data analysis.....	42
<b>CHAPTER FOUR: RESULTS.....</b>	<b>43</b>
4.1 Sample population distribution .....	43
4.2 Haemostatic profiles of type 2 diabetes.....	45
4.2.1 Prevalence of hypercoagulability.....	47
4.3 Risk factors and patient attribute associated with hypercoagulable state.....	48
4.4 Determinants of hypercoagulability using binary logistic regression.....	51
4.5 Suitability of PT and APTT as markers for hypercoagulability.....	53
<b>CHAPTER FIVE: DISCUSSION</b>	
5.1 Haemostatic profiles of type 2 diabetes mellitus patients.....	58
5.2 Prevalence of hypercoagulability .....	63
5.3 Risk factors and patient attributes associated with a hypercoagulable state.....	63
5.3.1 Age and hypercoagulability.....	63
5.3.2 Glycaemic control and hypercoagulability.....	64
5.3.3 Duration of type 2 diabetes mellitus and hypercoagulability.....	64
5.3.4 Knowledge about the risk factors, complications and management.....	65
5.3.5 Body Mass Index and Hypercoagulability.....	66
5.4 Suitability of PT and APTT as markers for hypercoagulability.....	67
5.5 Study limitations.....	69
<b>CHAPTER SIX: CONCLUSION</b>	
6.0 Conclusion.....	70
<b>CHAPTER SEVEN</b>	
7.0 Recommendations.....	71
<b>References.....</b>	<b>72</b>

## **APPENDICES**

Appendix 1: Information sheet (English).....	79
Appendix 2: Information sheet (Bemba).....	81
Appendix 3: Consent Form (English).....	83
Appendix 4: Consent Form (Bemba).....	85
Appendix 5: Questionnaire.....	86
Appendix 6: Laboratory Data collection forms.....	91
Appendix 7: Authorization Letters.....	93
Appendix 8: Supervisor’s Curriculum vitae.....	98
Appendix 9: Glucose estimation.....	101
Appendix 10: Cholesterol estimation.....	102
Appendix 11: PT estimation.....	103
Appendix 12: APTT estimation.....	104
Appendix 13: Fibrinogen estimation.....	105
Appendix 14: VWF estimation.....	106
Appendix 15: Glycated haemoglobin estimation.....	114

## LIST OF FIGURES

Figure 1.1: Virchows Triad.....	2
Figure 2.1: Mechanisms of endothelial dysfunction in Diabetes Mellitus.....	13
Figure 2.2: Prothrombotic mechanisms in Diabetes Mellitus.....	15
Figure 2.3: Mechanisms of increased risk for thrombosis with elevated fibrinogen.....	22
Figure 4.1: Demographic variables of study participants.....	44
Figure 4.2: Correlation between vWF and Fibrinogen plasma concentration.....	54
Figure 4.3: Correlation between vWF and Fibrinogen plasma concentration.....	55
Figure 4.4: Correlation between vWF and Prothrombin time.....	55

## LIST OF TABLES

Table 1.1: Study variables and their cut-off points.....	33
Table 4.1: Haemostatic profiles of type 2 diabetes mellitus patients and control Participants-Independent T-test parameters.....	45
Table 4.2: Haemostatic profiles of type 2 diabetes mellitus patients in males and Females-Independent T-test parameters.....	46
Table 4.3: Comparison of hypercoagulability between type 2 diabetes mellitus patients and control participants.....	47
Table 4.4: Proportion of type 2 diabetes mellitus patients with hypercoagulability according to patient attributes.....	48
Table 4.5: Binary logistic regression results: likelihood of hypercoagulability among type 2 diabetes mellitus patients based on patient attributes.....	51
Table 4.6: Comparison of VWF results and PT test results.....	56
Table 4.7: Comparison of VWF results and APTT test results.....	56
Table 4.8 Quality evaluation of parameters of PT and APTT.....	57

## **LIST OF ABBREVIATIONS**

AGEs- Advanced Glycation End Products

ANOVA- Analysis of Variance

APTT– Activated Partial Thromboplastin Time

BMI- Body Mass Index

CEBM -Center for evidence Based Medicine

Da- Dalton

DBP – Diastolic Blood Pressure

DM- Diabetes Mellitus

EDTA-Ethylenediaminetetraacetic acid

ENOS- Endothelial Nitric Oxide synthase

FBC- Full Blood Count

FBG – Fasting Blood Glucose

HbA1C-Glycated Haemoglobin

IFG-Impaired Fasting Glucose

MOH – Ministry of Health

NCH – Ndola Central Hospital

NO- Nitric Oxide

OPD- Out patient Department

PAI- Plasminogen activator inhibitor

PEDF- Pigment Epithelium Derived Factor

PT – Prothrombin Time

PPV- Positive Predictive Value

ROS- Reactive Oxygen Species

SBP – Systolic Blood Pressure

TAT- Thrombin-Antithrombin complex

TF-Tissue factor

tPA- Tissue plasminogen activator

T2DM- Type 2 Diabetes Mellitus

UNFPA- United Nations Population Fund

UNZA-BREC- University of Zambia Biomedical Research Ethics Committee

VTE-Venous thromboembolism

VWF – von Willebrands factor

WHO – World Health Organisation

ZDHS-Zambia Demographic health Survey

## DEFINITIONS AND ACRONYMS

**Advanced Glycation End Products** – Proteins or lipids that become covalently bonded to a sugar molecule such as glucose without the controlling action of an enzyme.

**Atherosclerosis** – A condition in which an artery wall thickens as a result of the accumulation of fatty materials such as cholesterol.

**Atherothrombosis**- atherosclerotic lesion disruption with superimposed thrombus formation.

**Body Mass Index**- A proxy for human body fat based on an individual's weight and height. Calculated by dividing individual's body mass by the square of his or her height.

**Fibrinolysis**- Breakdown of fibrin, usually by the enzymatic action of plasmin.

**Haemostasis**- Arrest of bleeding by the physiological properties of vasoconstriction and coagulation or by surgical means.

**Hypercoagulability**- Abnormality of blood coagulation that increases the risk of thrombosis.

**Plasminogen**- An inactive precursor of a serine protease plasmin.

**Prostacyclin**- A member of the family of lipid molecules known as eicosanoids. Inhibits platelet activation and is also an effective vasodilator.

**Reactive Oxygen Species**-Molecules or ions formed by the incomplete electron reduction of oxygen.

**Thrombosis**- Formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system.

**Thromboxane**- Any of several substances that are produced especially by platelets, formed from endoperoxides, cause constriction of vascular and bronchial smooth muscle and promote blood clotting.

**Tissue factor**- Cell surface receptor for factor VIIa, necessary for initiation of the extrinsic coagulation pathway.